| Characteristic . | Group A (n = 269) . | Group B (n = 212) . | Group C (n = 190) . | P . |
|---|---|---|---|---|
| Age (y), median (IQR) | 45 (30-59) | 51.5 (40.5-60) | 50 (41-58) | <.0001 |
| <55 y (%) | 181 (67.3) | 117 (55.2) | 112 (58.9) | .02 |
| ≥55 y (%) | 88 (32.7) | 95 (45.8) | 78 (41.1) | |
| Sex (%) | Male: 88 (32.7) | Male: 50 (23.6) | Male: 55 (28.9) | .90 |
| Female: 181 (67.3) | Female: 162 (73.4) | Female: 135 (71.1) | ||
| Preoperative metabolic equivalent of task (%) | 81 (30.1) | 109 (44.3) | 126 (50.0) | <.0001 |
| Tumor size (cm) Median (IQR) | 4 (2.5-5.0) | 3.8 (2.5-5.0) | 4.0 (3.0-6.0) | .043 |
| Histopathology (%) | FTC: 99 (36.8) | FTC: 111 (52.4) | FTC: 123 (64.7) | <.0001 |
| PTC: 157 (58.4) | PTC:94 (44.3) | PTC: 59 (31.1) | ||
| HTC: 13 (4.8) | HTC: 38 (17) | HTC: 8 (4.2) | ||
| Primary surgery (%) | ||||
| Total thyroidectomy | 171 (63.6) | 136 (64.2) | 129 (67.9) | .622 |
| Less than total | 98 (36.4) | 76 (35.8) | 61(32.1) | |
| T staging (%) | .016 | |||
| TX/T1/T2 | 138 (51.3) | 131 (61.7) | 98 (51.5) | |
| T3/T4 | 131 (48.7) | 81 (38.3) | 92 (48.5) | |
| N staging (%) | <.0001 | |||
| NX/N0 | 148 (55.0) | 149 (70.3) | 150 (79.0) | |
| N1 | 121 (45.0) | 63 (29.7) | 40 (21.0) | |
| Lung metastases (%) | 190 (70.6) | 95 (44.8) | 82 (43.2) | <.0001 |
| Diffuse pulmonary | 31 (11.5) | 6 (2.8) | 3 (1.6) | |
| Micronodular | 105 (39.0) | 49 (23.1) | 33 (17.4) | |
| Macronodular | 54 (20.1) | 40 (18.9) | 46 (24.2) | |
| Bone metastases (%) | 137 (50.9) | 159 (75.0) | 166 (87.4) | <.0001 |
| Single | 27 (10.0) | 23 (10.8) | 20 (10.5) | |
| Multiple(≥2) | 110 (40.9) | 136 (64.2) | 146 (76.9) | |
| Bone and lungs with other rare sites of distant metastases (%) | 61 (22.6) | 51 (24.0) | 63 (33.1) | .025 |
| Median cumulative activity (mCi) IQR | 405 (300-550) | 800 (750-950) | 1350(1220-1551) | <.0001 |
| Median follow-up period (mo) IQR | 57 (24.0-113.0) | 70.0 (41.0-130.0) | 122 (82.0-180.0) | <.0001 |
| Last 131I-WBS (%) | <.0001 | |||
| Negative/positive | 132 (49.1)/137 (50.9) | 55 (25.9)/157 (74.1) | 23 (12.1)/167 (87.9) | |
| EBRT (%) | 33 (12.3) | 49 (23.1) | 87 (45.8) | <.0001 |
| TKI (%) | 15 (5.6) | 10 (4.7) | 42 (21.6) | <.0001 |
| Adverse events (%) | 3 (1.1) | 12 (5.7) | 25 (12.1) | <.0001 |
| Patients alive with disease status (%) | CR: 107 (47.8) | CR: 41 (32.5) | CR: 21 (30.9) | <.0001 |
| PR: 106 (47.3) | PR: 79(62.7) | PR: 43 (63.2) | ||
| PD: 11 (4.9) | PD: 6 (4.8) | PD: 4 (5.9) | ||
| Total deaths at the time of reporting (%) | 45 (16.7) | 86 (40.6) | 122 (64.2) | <.0001 |
| Characteristic . | Group A (n = 269) . | Group B (n = 212) . | Group C (n = 190) . | P . |
|---|---|---|---|---|
| Age (y), median (IQR) | 45 (30-59) | 51.5 (40.5-60) | 50 (41-58) | <.0001 |
| <55 y (%) | 181 (67.3) | 117 (55.2) | 112 (58.9) | .02 |
| ≥55 y (%) | 88 (32.7) | 95 (45.8) | 78 (41.1) | |
| Sex (%) | Male: 88 (32.7) | Male: 50 (23.6) | Male: 55 (28.9) | .90 |
| Female: 181 (67.3) | Female: 162 (73.4) | Female: 135 (71.1) | ||
| Preoperative metabolic equivalent of task (%) | 81 (30.1) | 109 (44.3) | 126 (50.0) | <.0001 |
| Tumor size (cm) Median (IQR) | 4 (2.5-5.0) | 3.8 (2.5-5.0) | 4.0 (3.0-6.0) | .043 |
| Histopathology (%) | FTC: 99 (36.8) | FTC: 111 (52.4) | FTC: 123 (64.7) | <.0001 |
| PTC: 157 (58.4) | PTC:94 (44.3) | PTC: 59 (31.1) | ||
| HTC: 13 (4.8) | HTC: 38 (17) | HTC: 8 (4.2) | ||
| Primary surgery (%) | ||||
| Total thyroidectomy | 171 (63.6) | 136 (64.2) | 129 (67.9) | .622 |
| Less than total | 98 (36.4) | 76 (35.8) | 61(32.1) | |
| T staging (%) | .016 | |||
| TX/T1/T2 | 138 (51.3) | 131 (61.7) | 98 (51.5) | |
| T3/T4 | 131 (48.7) | 81 (38.3) | 92 (48.5) | |
| N staging (%) | <.0001 | |||
| NX/N0 | 148 (55.0) | 149 (70.3) | 150 (79.0) | |
| N1 | 121 (45.0) | 63 (29.7) | 40 (21.0) | |
| Lung metastases (%) | 190 (70.6) | 95 (44.8) | 82 (43.2) | <.0001 |
| Diffuse pulmonary | 31 (11.5) | 6 (2.8) | 3 (1.6) | |
| Micronodular | 105 (39.0) | 49 (23.1) | 33 (17.4) | |
| Macronodular | 54 (20.1) | 40 (18.9) | 46 (24.2) | |
| Bone metastases (%) | 137 (50.9) | 159 (75.0) | 166 (87.4) | <.0001 |
| Single | 27 (10.0) | 23 (10.8) | 20 (10.5) | |
| Multiple(≥2) | 110 (40.9) | 136 (64.2) | 146 (76.9) | |
| Bone and lungs with other rare sites of distant metastases (%) | 61 (22.6) | 51 (24.0) | 63 (33.1) | .025 |
| Median cumulative activity (mCi) IQR | 405 (300-550) | 800 (750-950) | 1350(1220-1551) | <.0001 |
| Median follow-up period (mo) IQR | 57 (24.0-113.0) | 70.0 (41.0-130.0) | 122 (82.0-180.0) | <.0001 |
| Last 131I-WBS (%) | <.0001 | |||
| Negative/positive | 132 (49.1)/137 (50.9) | 55 (25.9)/157 (74.1) | 23 (12.1)/167 (87.9) | |
| EBRT (%) | 33 (12.3) | 49 (23.1) | 87 (45.8) | <.0001 |
| TKI (%) | 15 (5.6) | 10 (4.7) | 42 (21.6) | <.0001 |
| Adverse events (%) | 3 (1.1) | 12 (5.7) | 25 (12.1) | <.0001 |
| Patients alive with disease status (%) | CR: 107 (47.8) | CR: 41 (32.5) | CR: 21 (30.9) | <.0001 |
| PR: 106 (47.3) | PR: 79(62.7) | PR: 43 (63.2) | ||
| PD: 11 (4.9) | PD: 6 (4.8) | PD: 4 (5.9) | ||
| Total deaths at the time of reporting (%) | 45 (16.7) | 86 (40.6) | 122 (64.2) | <.0001 |
Total numbers are highlighted as bold.
Abbreviations: CR, complete response; EBRT, external beam radiotherapy; FTC, follicular thyroid cancer; HTC, Hurtle cell thyroid cancer; IQR, interquartile range; PD, progressive disease; PR, partial response; PTC, papillary thyroid cancer; TKI, tyrosine kinase inhibitors; WBS, whole body scintigraphy.
| Characteristic . | Group A (n = 269) . | Group B (n = 212) . | Group C (n = 190) . | P . |
|---|---|---|---|---|
| Age (y), median (IQR) | 45 (30-59) | 51.5 (40.5-60) | 50 (41-58) | <.0001 |
| <55 y (%) | 181 (67.3) | 117 (55.2) | 112 (58.9) | .02 |
| ≥55 y (%) | 88 (32.7) | 95 (45.8) | 78 (41.1) | |
| Sex (%) | Male: 88 (32.7) | Male: 50 (23.6) | Male: 55 (28.9) | .90 |
| Female: 181 (67.3) | Female: 162 (73.4) | Female: 135 (71.1) | ||
| Preoperative metabolic equivalent of task (%) | 81 (30.1) | 109 (44.3) | 126 (50.0) | <.0001 |
| Tumor size (cm) Median (IQR) | 4 (2.5-5.0) | 3.8 (2.5-5.0) | 4.0 (3.0-6.0) | .043 |
| Histopathology (%) | FTC: 99 (36.8) | FTC: 111 (52.4) | FTC: 123 (64.7) | <.0001 |
| PTC: 157 (58.4) | PTC:94 (44.3) | PTC: 59 (31.1) | ||
| HTC: 13 (4.8) | HTC: 38 (17) | HTC: 8 (4.2) | ||
| Primary surgery (%) | ||||
| Total thyroidectomy | 171 (63.6) | 136 (64.2) | 129 (67.9) | .622 |
| Less than total | 98 (36.4) | 76 (35.8) | 61(32.1) | |
| T staging (%) | .016 | |||
| TX/T1/T2 | 138 (51.3) | 131 (61.7) | 98 (51.5) | |
| T3/T4 | 131 (48.7) | 81 (38.3) | 92 (48.5) | |
| N staging (%) | <.0001 | |||
| NX/N0 | 148 (55.0) | 149 (70.3) | 150 (79.0) | |
| N1 | 121 (45.0) | 63 (29.7) | 40 (21.0) | |
| Lung metastases (%) | 190 (70.6) | 95 (44.8) | 82 (43.2) | <.0001 |
| Diffuse pulmonary | 31 (11.5) | 6 (2.8) | 3 (1.6) | |
| Micronodular | 105 (39.0) | 49 (23.1) | 33 (17.4) | |
| Macronodular | 54 (20.1) | 40 (18.9) | 46 (24.2) | |
| Bone metastases (%) | 137 (50.9) | 159 (75.0) | 166 (87.4) | <.0001 |
| Single | 27 (10.0) | 23 (10.8) | 20 (10.5) | |
| Multiple(≥2) | 110 (40.9) | 136 (64.2) | 146 (76.9) | |
| Bone and lungs with other rare sites of distant metastases (%) | 61 (22.6) | 51 (24.0) | 63 (33.1) | .025 |
| Median cumulative activity (mCi) IQR | 405 (300-550) | 800 (750-950) | 1350(1220-1551) | <.0001 |
| Median follow-up period (mo) IQR | 57 (24.0-113.0) | 70.0 (41.0-130.0) | 122 (82.0-180.0) | <.0001 |
| Last 131I-WBS (%) | <.0001 | |||
| Negative/positive | 132 (49.1)/137 (50.9) | 55 (25.9)/157 (74.1) | 23 (12.1)/167 (87.9) | |
| EBRT (%) | 33 (12.3) | 49 (23.1) | 87 (45.8) | <.0001 |
| TKI (%) | 15 (5.6) | 10 (4.7) | 42 (21.6) | <.0001 |
| Adverse events (%) | 3 (1.1) | 12 (5.7) | 25 (12.1) | <.0001 |
| Patients alive with disease status (%) | CR: 107 (47.8) | CR: 41 (32.5) | CR: 21 (30.9) | <.0001 |
| PR: 106 (47.3) | PR: 79(62.7) | PR: 43 (63.2) | ||
| PD: 11 (4.9) | PD: 6 (4.8) | PD: 4 (5.9) | ||
| Total deaths at the time of reporting (%) | 45 (16.7) | 86 (40.6) | 122 (64.2) | <.0001 |
| Characteristic . | Group A (n = 269) . | Group B (n = 212) . | Group C (n = 190) . | P . |
|---|---|---|---|---|
| Age (y), median (IQR) | 45 (30-59) | 51.5 (40.5-60) | 50 (41-58) | <.0001 |
| <55 y (%) | 181 (67.3) | 117 (55.2) | 112 (58.9) | .02 |
| ≥55 y (%) | 88 (32.7) | 95 (45.8) | 78 (41.1) | |
| Sex (%) | Male: 88 (32.7) | Male: 50 (23.6) | Male: 55 (28.9) | .90 |
| Female: 181 (67.3) | Female: 162 (73.4) | Female: 135 (71.1) | ||
| Preoperative metabolic equivalent of task (%) | 81 (30.1) | 109 (44.3) | 126 (50.0) | <.0001 |
| Tumor size (cm) Median (IQR) | 4 (2.5-5.0) | 3.8 (2.5-5.0) | 4.0 (3.0-6.0) | .043 |
| Histopathology (%) | FTC: 99 (36.8) | FTC: 111 (52.4) | FTC: 123 (64.7) | <.0001 |
| PTC: 157 (58.4) | PTC:94 (44.3) | PTC: 59 (31.1) | ||
| HTC: 13 (4.8) | HTC: 38 (17) | HTC: 8 (4.2) | ||
| Primary surgery (%) | ||||
| Total thyroidectomy | 171 (63.6) | 136 (64.2) | 129 (67.9) | .622 |
| Less than total | 98 (36.4) | 76 (35.8) | 61(32.1) | |
| T staging (%) | .016 | |||
| TX/T1/T2 | 138 (51.3) | 131 (61.7) | 98 (51.5) | |
| T3/T4 | 131 (48.7) | 81 (38.3) | 92 (48.5) | |
| N staging (%) | <.0001 | |||
| NX/N0 | 148 (55.0) | 149 (70.3) | 150 (79.0) | |
| N1 | 121 (45.0) | 63 (29.7) | 40 (21.0) | |
| Lung metastases (%) | 190 (70.6) | 95 (44.8) | 82 (43.2) | <.0001 |
| Diffuse pulmonary | 31 (11.5) | 6 (2.8) | 3 (1.6) | |
| Micronodular | 105 (39.0) | 49 (23.1) | 33 (17.4) | |
| Macronodular | 54 (20.1) | 40 (18.9) | 46 (24.2) | |
| Bone metastases (%) | 137 (50.9) | 159 (75.0) | 166 (87.4) | <.0001 |
| Single | 27 (10.0) | 23 (10.8) | 20 (10.5) | |
| Multiple(≥2) | 110 (40.9) | 136 (64.2) | 146 (76.9) | |
| Bone and lungs with other rare sites of distant metastases (%) | 61 (22.6) | 51 (24.0) | 63 (33.1) | .025 |
| Median cumulative activity (mCi) IQR | 405 (300-550) | 800 (750-950) | 1350(1220-1551) | <.0001 |
| Median follow-up period (mo) IQR | 57 (24.0-113.0) | 70.0 (41.0-130.0) | 122 (82.0-180.0) | <.0001 |
| Last 131I-WBS (%) | <.0001 | |||
| Negative/positive | 132 (49.1)/137 (50.9) | 55 (25.9)/157 (74.1) | 23 (12.1)/167 (87.9) | |
| EBRT (%) | 33 (12.3) | 49 (23.1) | 87 (45.8) | <.0001 |
| TKI (%) | 15 (5.6) | 10 (4.7) | 42 (21.6) | <.0001 |
| Adverse events (%) | 3 (1.1) | 12 (5.7) | 25 (12.1) | <.0001 |
| Patients alive with disease status (%) | CR: 107 (47.8) | CR: 41 (32.5) | CR: 21 (30.9) | <.0001 |
| PR: 106 (47.3) | PR: 79(62.7) | PR: 43 (63.2) | ||
| PD: 11 (4.9) | PD: 6 (4.8) | PD: 4 (5.9) | ||
| Total deaths at the time of reporting (%) | 45 (16.7) | 86 (40.6) | 122 (64.2) | <.0001 |
Total numbers are highlighted as bold.
Abbreviations: CR, complete response; EBRT, external beam radiotherapy; FTC, follicular thyroid cancer; HTC, Hurtle cell thyroid cancer; IQR, interquartile range; PD, progressive disease; PR, partial response; PTC, papillary thyroid cancer; TKI, tyrosine kinase inhibitors; WBS, whole body scintigraphy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
